Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kunal Nepali

Showing results (61-70 of 83) with videos related to

Pageof 9
Sort By:
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|March 19, 2021
A novel histone deacetylase inhibitor MPT0L184 dysregulates cell-cycle checkpoints and initiates unscheduled mitotic signalingTing-Yu Chang, Kunal Nepali, Yi-Ying Chen, et al.
Journal of Advanced Research|June 25, 2022
Rational design of synthetically tractable HDAC6/HSP90 dual inhibitors to destroy immune-suppressive tumor microenvironmentTung-Yun Wu, Michael Chen, I-Chung Chen, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry|November 3, 2023
Flavone-based dual PARP-Tubulin inhibitor manifesting efficacy against endometrial cancerSachin Sharma, Kavya Chandra, Aliva Naik, et al.
Cancer Letters|February 4, 2024
Dual inhibition of CYP17A1 and HDAC6 by abiraterone-installed hydroxamic acid overcomes temozolomide resistance in glioblastoma through inducing DNA damage and oxidative stressRam Sharma, Yung-Hsiao Chiang, Hsien-Chung Chen, et al.
Journal of Medicinal Chemistry|December 15, 2021
Installation of Pargyline, a LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer AgentRitu Ojha, I-Chung Chen, Chien-Ming Hsieh, et al.
Journal of Medicinal Chemistry|September 25, 2024
Syntheses of LSD1/HDAC Inhibitors with Demonstrated Efficacy against Colorectal Cancer: <i>In Vitro</i> and <i>In Vivo</i> Studies Including Patient-Derived OrganoidsPo-Yu Chou, Mei-Jung Lai, Kelvin K Tsai, et al.
Bioorganic & Medicinal Chemistry|July 13, 2010
Synthesis and biological evaluation of arylidene analogues of Meldrum's acid as a new class of antimalarial and antioxidant agentsHarmeet S Sandhu, Sameer Sapra, Mukesh Gupta, et al.
Bioorganic Chemistry|July 27, 2019
Amide-tethered quinoline-resorcinol conjugates as a new class of HSP90 inhibitors suppressing the growth of prostate cancer cellsKunal Nepali, Mei-Hsiang Lin, Min-Wu Chao, et al.
Heliyon|July 14, 2018
Antitumour, acute toxicity and molecular modeling studies of 4-(pyridin-4-yl)-6-(thiophen-2-yl) pyrimidin-2(1H)-one against Ehrlich ascites carcinoma and sarcoma-180Dinesh Kumar, Pooja Sharma, Kunal Nepali, et al.
European Journal of Medicinal Chemistry|September 18, 2024
Rationally designed febuxostat-based hydroxamic acid and its pH-Responsive nanoformulation elicits anti-tumor activityRitika, Zi-Yi Liao, Pin-Yu Chen, et al.
Pageof 9

Showing results (61-70 of 83) with videos related to

Sort By:
Pageof 9
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|March 19, 2021
A novel histone deacetylase inhibitor MPT0L184 dysregulates cell-cycle checkpoints and initiates unscheduled mitotic signalingTing-Yu Chang, Kunal Nepali, Yi-Ying Chen, et al.
Journal of Advanced Research|June 25, 2022
Rational design of synthetically tractable HDAC6/HSP90 dual inhibitors to destroy immune-suppressive tumor microenvironmentTung-Yun Wu, Michael Chen, I-Chung Chen, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry|November 3, 2023
Flavone-based dual PARP-Tubulin inhibitor manifesting efficacy against endometrial cancerSachin Sharma, Kavya Chandra, Aliva Naik, et al.
Cancer Letters|February 4, 2024
Dual inhibition of CYP17A1 and HDAC6 by abiraterone-installed hydroxamic acid overcomes temozolomide resistance in glioblastoma through inducing DNA damage and oxidative stressRam Sharma, Yung-Hsiao Chiang, Hsien-Chung Chen, et al.
Journal of Medicinal Chemistry|December 15, 2021
Installation of Pargyline, a LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer AgentRitu Ojha, I-Chung Chen, Chien-Ming Hsieh, et al.
Journal of Medicinal Chemistry|September 25, 2024
Syntheses of LSD1/HDAC Inhibitors with Demonstrated Efficacy against Colorectal Cancer: <i>In Vitro</i> and <i>In Vivo</i> Studies Including Patient-Derived OrganoidsPo-Yu Chou, Mei-Jung Lai, Kelvin K Tsai, et al.
Bioorganic & Medicinal Chemistry|July 13, 2010
Synthesis and biological evaluation of arylidene analogues of Meldrum's acid as a new class of antimalarial and antioxidant agentsHarmeet S Sandhu, Sameer Sapra, Mukesh Gupta, et al.
Bioorganic Chemistry|July 27, 2019
Amide-tethered quinoline-resorcinol conjugates as a new class of HSP90 inhibitors suppressing the growth of prostate cancer cellsKunal Nepali, Mei-Hsiang Lin, Min-Wu Chao, et al.
Heliyon|July 14, 2018
Antitumour, acute toxicity and molecular modeling studies of 4-(pyridin-4-yl)-6-(thiophen-2-yl) pyrimidin-2(1H)-one against Ehrlich ascites carcinoma and sarcoma-180Dinesh Kumar, Pooja Sharma, Kunal Nepali, et al.
European Journal of Medicinal Chemistry|September 18, 2024
Rationally designed febuxostat-based hydroxamic acid and its pH-Responsive nanoformulation elicits anti-tumor activityRitika, Zi-Yi Liao, Pin-Yu Chen, et al.
Pageof 9